# Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidine

> **NCT07683949** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Seoul National University Bundang Hospital** · enrollment: 93 (estimated)

## Conditions studied

- Advanced Colorectal Cancer (Part 1)

## Interventions

- **COMBINATION_PRODUCT:** Lenvanib (Lenvatinib),Xeloda (capecitabine)

## Key facts

- **NCT ID:** NCT07683949
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-06-15
- **Primary completion:** 2029-10-31
- **Final completion:** 2029-10-31
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2026-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683949, "Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidine". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07683949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*